Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
01 June 1972Website:
http://www.bms.comNext earnings report:
26 July 2024Last dividends:
04 April 2024Next dividends:
05 July 2024Price
after hours | 8 min agoAnalysts recommendations
Institutional Ownership
Included in screeners
BMY Latest News
AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices, high dividend yields, and potential for market-beating returns. W.P. Carey yields 6.3% and offers growth potential through European property acquisitions, while Bristol Myers Squibb gives a 5.6% yield and has growth prospects driven by a strong drug pipeline.
Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs.
Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, why I sold them, my barbell strategy, and how much cash I am holding in my investment portfolios.
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this period.
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be.
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.
What type of business is Bristol-Myers Squibb?
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, licensing, manufacturing, marketing, and sale of biopharmaceutical products. Bristol-Myers pharmaceutical products are chemically synthesized or low molecular weight drugs for the following therapeutic areas: oncology; immunology with priorities in psoriasis, lupus, cancer, inflammatory bowel diseases, HIV; cardiovascular with priority in heart disease; fibrotic diseases of the lungs and liver; hepatitis B, C. The line of pharmaceuticals is represented by 10 trade brands. The Bristol-Myers company was registered in 1933 and essentially is the successor of a New York pharmaceutical manufacturer that has been in operation since 1887. Bristol-Myers' major manufacturing facilities are located in the United States, Puerto Rico, Ireland, France, and Italy.
What sector is Bristol-Myers Squibb in?
Bristol-Myers Squibb is in the Healthcare sector
What industry is Bristol-Myers Squibb in?
Bristol-Myers Squibb is in the Drug Manufacturers - General industry
What country is Bristol-Myers Squibb from?
Bristol-Myers Squibb is headquartered in United States
When did Bristol-Myers Squibb go public?
Bristol-Myers Squibb initial public offering (IPO) was on 01 June 1972
What is Bristol-Myers Squibb website?
https://www.bms.com
Is Bristol-Myers Squibb in the S&P 500?
Yes, Bristol-Myers Squibb is included in the S&P 500 index
Is Bristol-Myers Squibb in the NASDAQ 100?
No, Bristol-Myers Squibb is not included in the NASDAQ 100 index
Is Bristol-Myers Squibb in the Dow Jones?
No, Bristol-Myers Squibb is not included in the Dow Jones index
When does Bristol-Myers Squibb report earnings?
The next expected earnings date for Bristol-Myers Squibb is 26 July 2024